Diabetic db/db mice do not develop heart failure upon pressure overload: A longitudinal in vivo PET, MRI, and MRS study on cardiac metabolic, structural, and functional adaptations

Cardiovascular Research

Volumn 113, Issue 10, 2017, Pages 1148-1160

  Abdurrachim, Desiree ^a   Nabben, Miranda ^a,b   Hoerr, Verena ^c,d   Kuhlmann, Michael T ^e   Bovenkamp, Philipp ^c   Ciapaite, Jolita ^f   Geraets, Ilvy M E ^b   Coumans, Will ^b   Luiken, Joost J F P ^b   Glatz, Jan F C ^b   Schäfers, Michael ^e,g   Nicolay, Klaas ^a   Faber, Cornelius ^c   Hermann, Sven ^e,g   Prompers, Jeanine J ^a  

^a EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d JENA UNIVERSITY HOSPITAL   (Germany)

^e INST OF REPRO MED OF THE UNIV   (Germany)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Diabetes; Heart failure; In vivo imaging techniques; Pressure overload; Substrate metabolism

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; FLUORINE 18; GLUCOSE; PROTEIN KINASE D; RNA; FATTY ACID; FLUORODEOXYGLUCOSE F 18; PROTEIN KINASE C; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTIC CONSTRICTION; ARTICLE; BODY WEIGHT; CITRIC ACID CYCLE; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE COURSE; EX VIVO STUDY; FATTY ACID OXIDATION; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; HEART LEFT VENTRICLE MASS; HEART MUSCLE METABOLISM; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; IN VIVO STUDY; LIPID STORAGE; LONGITUDINAL STUDY; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATIVE PHOSPHORYLATION; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEOMICS; PROTON NUCLEAR MAGNETIC RESONANCE; RESPIROMETRY; SURGICAL MORTALITY; WESTERN BLOTTING; ADAPTATION; ANIMAL; AORTA; ARTERIAL PRESSURE; BLOOD; C57BL MOUSE; CARDIAC MUSCLE; DIABETIC COMPLICATION; DIAGNOSTIC IMAGING; DISEASE MODEL; ENERGY METABOLISM; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; LIGATION; METABOLISM; PATHOPHYSIOLOGY; PHOSPHORYLATION; PREDICTIVE VALUE; SURGERY; TIME FACTOR;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; AORTA; ARTERIAL PRESSURE; BLOOD GLUCOSE; CONSTRICTION; DIABETES COMPLICATIONS; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; FATTY ACIDS; FLUORODEOXYGLUCOSE F18; HEART FAILURE; MAGNETIC RESONANCE IMAGING; MALE; MICE, INBRED C57BL; MYOCARDIUM; PHOSPHORYLATION; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE C; PROTON MAGNETIC RESONANCE SPECTROSCOPY; RADIOPHARMACEUTICALS; TIME FACTORS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 85031718578     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvx100     Document Type: Article

References (56)

1. Ingwall JS. Energy metabolism in heart failure and remodelling. Cardiovasc Res 2009;81:412-419.
2. Pereira RO, Wende AR, Olsen C, Soto J, Rawlings T, Zhu Y, Anderson SM, Abel ED. Inducible overexpression of GLUT1 prevents mitochondrial dysfunction and attenuates structural remodeling in pressure overload but does not prevent left ventricular dysfunction. J Am Heart Assoc 2013;2:e000301.
3. Kolwicz SC, Jr., Olson DP, Marney LC, Garcia-Menendez L, Synovec RE, Tian R. Cardiac-specific deletion of acetyl CoA carboxylase 2 prevents metabolic remodeling during pressure-overload hypertrophy. Circ Res 2012;111:728-738.
4. Allard MF, Schonekess BO, Henning SL, English DR, Lopaschuk GD. Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am J Physiol 1994;267:H742-H750.
5. Christe ME, Rodgers RL. Altered glucose and fatty acid oxidation in hearts of the spontaneously hypertensive rat. J Mol Cell Cardiol 1994;26:1371-1375.
6. Zhong M, Alonso CE, Taegtmeyer H, Kundu BK. Quantitative PET imaging detects early metabolic remodeling in a mouse model of pressure-overload left ventricular hypertrophy in vivo. J Nucl Med 2013;54:609-615.
7. 31P spectroscopic chemical shift imaging. Eur Radiol 2005;15:319-323.
8. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, Pabst T, Ertl G, Hahn D, Ingwall JS, Kochsiek K. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997;96:2190-2196.
9. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004;27:1879-1884.
10. Oakes ND, Thalen P, Aasum E, Edgley A, Larsen T, Furler SM, Ljung B, Severson D. Cardiac metabolism in mice: tracer method developments and in vivo application revealing profound metabolic inflexibility in diabetes. Am J Physiol Endocrinol Metab 2006;290:E870-E881.
11. Scheuermann-Freestone M, Madsen PL, Manners D, Blamire AM, Buckingham RE, Styles P, Radda GK, Neubauer S, Clarke K. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation 2003;107:3040-3046.
12. Diamant M, Lamb HJ, Groeneveld Y, Endert EL, Smit JW, Bax JJ, Romijn JA, de Roos A, Radder JK. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol 2003;42:328-335.
13. Liao R, Jain M, Cui L, D'agostino J, Aiello F, Luptak I, Ngoy S, Mortensen RM, Tian R. Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. Circulation 2002;106:2125-2131.
14. Kienesberger PC, Pulinilkunnil T, Sung MM, Nagendran J, Haemmerle G, Kershaw EE, Young ME, Light PE, Oudit GY, Zechner R, Dyck JR. Myocardial ATGL overexpres-sion decreases the reliance on fatty acid oxidation and protects against pressure overload-induced cardiac dysfunction. Mol Cell Biol 2012;32:740-750.
15. Luptak I, Balschi JA, Xing Y, Leone TC, Kelly DP, Tian R. Decreased contractile and metabolic reserve in peroxisome proliferator-activated receptor-a-null hearts can be rescued by increasing glucose transport and utilization. Circulation 2005;112: 2339-2346.
16. Labinskyy V, Bellomo M, Chandler MP, Young ME, Lionetti V, Qanud K, Bigazzi F, Sampietro T, Stanley WC, Recchia FA. Chronic activation of peroxisome proliferator-activated receptor-alpha with fenofibrate prevents alterations in cardiac metabolic phenotype without changing the onset of decompensation in pacing-induced heart failure. J Pharmacol Exp Ther 2007;321:165-171.
17. Christopher BA, Huang HM, Berthiaume JM, McElfresh TA, Chen X, Croniger CM, Muzic RF, Jr, Chandler MP. Myocardial insulin resistance induced by high fat feeding in heart failure is associated with preserved contractile function. Am J Physiol Heart Circ Physiol 2010;299:H1917-H1927.
18. He L, Kim T, Long Q, Liu J, Wang P, Zhou Y, Ding Y, Prasain J, Wood PA, Yang Q. Carnitine palmitoyltransferase-1b deficiency aggravates pressure overload-induced cardiac hypertrophy caused by lipotoxicity. Circulation 2012;126:1705-1716.
19. Steinbusch LK, Luiken JJ, Vlasblom R, Chabowski A, Hoebers NT, Coumans WA, Vroegrijk IO, Voshol PJ, Ouwens DM, Glatz JF, Diamant M. Absence of fatty acid transporter CD36 protects against Western-type diet-related cardiac dysfunction following pressure overload in mice. Am J Physiol Endocrinol Metab 2011;301:E618-E627.
20. Arany Z, Novikov M, Chin S, Ma Y, Rosenzweig A, Spiegelman BM. Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-g coactivator 1a. Proc Natl Acad Sci U S A 2006;103:10086-10091.
21. Augustus AS, Buchanan J, Park TS, Hirata K, Noh HL, Sun J, Homma S, D'armiento J, Abel ED, Goldberg IJ. Loss of lipoprotein lipase-derived fatty acids leads to increased cardiac glucose metabolism and heart dysfunction. J Biol Chem 2006;281:8716-8723.
22. Abdurrachim D, Luiken JJ, Nicolay K, Glatz JF, Prompers JJ, Nabben M. Good and bad consequences of altered fatty acid metabolism in heart failure: evidence from mouse models. Cardiovasc Res 2015;106:194-205.
23. Lavie CJ, Alpert MA, Arena R, Mehra MR, Milani RV, Ventura HO. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. JACC Heart Fail 2013;1:93-102.
24. van Nierop BJ, van Assen HC, van Deel ED, Niesen LB, Duncker DJ, Strijkers GJ, Nicolay K. Phenotyping of left and right ventricular function in mouse models of compensated hypertrophy and heart failure with cardiac MRI. PLoS One 2013;8:e55424.
25. Shioi T, McMullen JR, Tarnavski O, Converso K, Sherwood MC, Manning WJ, Izumo S. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 2003;107:1664-1670.
26. Boluyt MO, Li ZB, Loyd AM, Scalia AF, Cirrincione GM, Jackson RR. The mTOR/ p70S6K signal transduction pathway plays a role in cardiac hypertrophy and influences expression of myosin heavy chain genes in vivo. Cardiovasc Drugs Ther 2004;18:257-267.
27. McMullen JR, Sherwood MC, Tarnavski O, Zhang L, Dorfman AL, Shioi T, Izumo S. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 2004;109:3050-3055.
28. Sen S, Kundu BK, Wu HC, Hashmi SS, Guthrie P, Locke LW, Roy RJ, Matherne GP, Berr SS, Terwelp M, Scott B, Carranza S, Frazier OH, Glover DK, Dillmann WH, Gambello MJ, Entman ML, Taegtmeyer H. Glucose regulation of load-induced mTOR signaling and ER stress in mammalian heart. J Am Heart Assoc 2013;2:e004796.
29. Takeishi Y, Huang Q, Abe J, Glassman M, Che W, Lee JD, Kawakatsu H, Lawrence EG, Hoit BD, Berk BC, Walsh RA. Src and multiple MAP kinase activation in cardiac hypertrophy and congestive heart failure under chronic pressure-overload: comparison with acute mechanical stretch. J Mol Cell Cardiol 2001;33:1637-1648.
30. Dirkx E, van Eys GJ, Schwenk RW, Steinbusch LK, Hoebers N, Coumans WA, Peters T, Janssen BJ, Brans B, Vogg AT, Neumann D, Glatz JF, Luiken JJ. Protein kinase-D1 overexpression prevents lipid-induced cardiac insulin resistance. J Mol Cell Cardiol 2014;76:208-217.
31. Harrison BC, Kim MS, van Rooij E, Plato CF, Papst PJ, Vega RB, McAnally JA, Richardson JA, Bassel-Duby R, Olson EN, McKinsey TA. Regulation of cardiac stress signaling by protein kinase D1. Mol Cell Biol 2006;26:3875-3888.
32. Anderson ME, Brown JH, Bers DM. CaMKII in myocardial hypertrophy and heart failure. J Mol Cell Cardiol 2011;51:468-473.
33. Olson EN, Backs J, McKinsey TA. Control of cardiac hypertrophy and heart failure by histone acetylation/deacetylation. Novartis Found Symp 2006;274:3-12. discussion 13-19, 152-155, 272-156.
34. van Bilsen M, Smeets PJ, Gilde AJ, van der Vusse GJ. Metabolic remodelling of the failing heart: the cardiac burn-out syndrome?. Cardiovasc Res 2004;61:218-226.
35. Kundu BK, Zhong M, Sen S, Davogustto G, Keller SR, Taegtmeyer H. Remodeling of glucose metabolism precedes pressure overload-induced left ventricular hypertrophy: review of a hypothesis. Cardiology 2015;130:211-220.
36. Sharov VG, Goussev A, Lesch M, Goldstein S, Sabbah HN. Abnormal mitochondrial function in myocardium of dogs with chronic heart failure. J Mol Cell Cardiol 1998;30:1757-1762.
37. Rosca MG, Vazquez EJ, Kerner J, Parland W, Chandler MP, Stanley W, Sabbah HN, Hoppel CL. Cardiac mitochondria in heart failure: decrease in respirasomes and oxi-dative phosphorylation. Cardiovasc Res 2008;80:30-39.
38. Lemieux H, Semsroth S, Antretter H, Hofer D, Gnaiger E. Mitochondrial respiratory control and early defects of oxidative phosphorylation in the failing human heart. Int J Biochem Cell Biol 2011;43:1729-1738.
39. Sharov VG, Todor AV, Silverman N, Goldstein S, Sabbah HN. Abnormal mitochon-drial respiration in failed human myocardium. J Mol Cell Cardiol 2000;32:2361-2367.
40. Fielitz J, Kim MS, Shelton JM, Qi X, Hill JA, Richardson JA, Bassel-Duby R, Olson EN. Requirement of protein kinase D1 for pathological cardiac remodeling. Proc Natl Acad Sci U S A 2008;105:3059-3063.
41. Yorikane R, Sakai S, Miyauchi T, Sakurai T, Sugishita Y, Goto K. Increased production of endothelin-1 in the hypertrophied rat heart due to pressure overload. FEBS Lett 1993;332:31-34.
42. Haworth RS, Roberts NA, Cuello F, Avkiran M. Regulation of protein kinase D activity in adult myocardium: novel counter-regulatory roles for protein kinase Ce and protein kinase A. J Mol Cell Cardiol 2007;43:686-695.
43. Huynh QK, McKinsey TA. Protein kinase D directly phosphorylates histone deacety-lase 5 via a random sequential kinetic mechanism. Arch Biochem Biophys 2006;450:141-148.
44. Kolwicz SC, Jr, Tian R. Glucose metabolism and cardiac hypertrophy. Cardiovasc Res 2011;90:194-201.
45. Kritzer MD, Li J, Passariello CL, Gayanilo M, Thakur H, Dayan J, Dodge-Kafka K, Kapiloff MS. The scaffold protein muscle A-kinase anchoring protein beta orchestrates cardiac myocyte hypertrophic signaling required for the development of heart failure. Circ Heart Fail 2014;7:663-672.
46. Aasum E, Belke DD, Severson DL, Riemersma RA, Cooper M, Andreassen M, Larsen TS. Cardiac function and metabolism in type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-a activator. Am J Physiol Heart Circ Physiol 2002;283: H949-H957.
47. 18F]fluoro-4-thiapalmitate, a novel PET fatty acid tracer. Am J Physiol Endocrinol Metab 2016;310:E452-E460.
48. Brainard RE, Watson LJ, Demartino AM, Brittian KR, Readnower RD, Boakye AA, Zhang D, Hoetker JD, Bhatnagar A, Baba SP, Jones SP. High fat feeding in mice is insufficient to induce cardiac dysfunction and does not exacerbate heart failure. PLoS One 2013;8:e83174.
49. Choi YS, de Mattos AB, Shao D, Li T, Nabben M, Kim M, Wang W, Tian R, Kolwicz SC. Jr., Preservation of myocardial fatty acid oxidation prevents diastolic dysfunction in mice subjected to angiotensin II infusion. J Mol Cell Cardiol 2016;100:64-71.
50. Zlobine I, Gopal K, Ussher JR. Lipotoxicity in obesity and diabetes-related cardiac dysfunction. Biochim Biophys Acta 2016;1861:1555-1568.
51. Glatz JF, Bonen A, Ouwens DM, Luiken JJ. Regulation of sarcolemmal transport of substrates in the healthy and diseased heart. Cardiovasc Drugs Ther 2006;20:471-476.
52. Gupta A, Chacko VP, Weiss RG. Abnormal energetics and ATP depletion in pressure-overload mouse hearts: in vivo high-energy phosphate concentration measures by non-invasive magnetic resonance. Am J Physiol Heart Circ Physiol 2009;297:H59-H64.
53. Maslov MY, Chacko VP, Stuber M, Moens AL, Kass DA, Champion HC, Weiss RG. Altered high-energy phosphate metabolism predicts contractile dysfunction and subsequent ventricular remodeling in pressure-overload hypertrophy mice. Am J Physiol Heart Circ Physiol 2007;292:H387-H391.
54. Hardy CJ, Weiss RG, Bottomley PA, Gerstenblith G. Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy. Am Heart J 1991;122:795-801.
55. Bashir A, Coggan AR, Gropler RJ. In vivo creatine kinase reaction kinetics at rest and stress in type II diabetic rat heart. Physiol Rep 2015;3:
56. Hall ME, Harmancey R, Stec DE. Lean heart: Role of leptin in cardiac hypertrophy and metabolism. World J Cardiol 2015;7:511-524.